US FDA Filing Mistake For Fintepla Dents Zogenix
Executive Summary
Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.
You may also be interested in...
Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price
The average list price of $96,000 per year is three times the cost of GW’s competing drug Epidiolex, but Zogenix is betting that the reduction in seizures seen in clinical trials will justify the expense.
March Madness: Upcoming US FDA Decision Dates To Watch
A dozen applications for new drugs and significant new indications are on the US FDA’s calendar of goal dates, including breakthrough-designated applications from Bristol-Myers Squibb and Boehringer Ingelheim.
Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.